Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/222855
Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Chemotherapy is assuming an increasingly important role in the treatment of malignant gliomas, of which temozolomide (TMZ ) is a key part. TMZ belongs to a class of second-generation imidazotetrazinone prodrugs that exhibit linear pharmacokinetics and do not require hepatic metabolism for activation to the active metabolite. New intravenous (iv) TMZ formulations have recently been approved based on studies of bioequivalence between iv and oral TMZ. The efficacy of TMZ was initially evaluated in patients with recurrent disease but phase II and III trials in newly diagnosed gliomas are available. The results of a large phase III trial that compared RT alone vs RT concomitant with oral TMZ created a new standard of adjuvant treatment. Efficacy data for iv TMZ on which its approval was based are those extrapolated from clinical trials with oral TMZ. No comparative data are available on the differences in tolerability and patient satisfaction between oral and iv formulations of TMZ, or for quality of life. New oral formulations could encourage the adherence of patients to treatment. Although patients presumably would prefer oral treatment, iv formulations may be an alternative in noncompliant patients or patients for whom good adherence could not be expected
Subject (English)
Citation
Citation
GARCÍA MARTÍN, Margarita, et al. Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations. Cancer Management and Research. 2009. Vol. 137-150. ISSN 1179-1322. [consulted: 15 of August of 2026]. Available at: https://hdl.handle.net/2445/222855